Nabriva Therapeutics up on Q2 revenue beat

Nabriva Therapeutics

06/08/2021 11:41

** Drugmaker's shares  NBRV.O  up 15% at $1.3 premarket; set
for their best day in more than 4 months
    ** Late on Thursday, company posted Q2 revenue of $8.2 mln,
vs est $6.0 mln - Refinitiv data
    ** Beat driven by launch of company's drug, Sivextro, to
treat acute bacterial skin infection  urn:newsml:reuters.com:*:nGNX42C5hv
    ** Up to Thursday's close, stock down 52% YTD

 (Reporting by Dania Nadeem)